New combo aims to tame Chemo's worst side effect in deadly lung cancer

NCT ID NCT05578326

Recruiting now Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether adding trilaciclib to the chemotherapy drug lurbinectedin can reduce severe neutropenia (a dangerous drop in white blood cells) in people with small cell lung cancer that has spread. About 30 participants will receive both drugs intravenously. The study focuses on safety and how well the combination works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trilaciclib and lurbinectedin
What this could lead to: If successful, this combination could reduce dangerous side effects (severe neutropenia) from chemotherapy and improve treatment tolerance for small cell lung cancer patients.
What could go wrong: This is a small Phase 2 trial with only 30 participants, so results may not apply broadly. The drugs may still cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm neutropenia small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER SMALL CELL LUNG CANCER

Contacts and locations

Locations

Dartmouth Hitchcock Medical Center
WITHDRAWN

Lebanon, New Hampshire, 03756, United States
Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.